Hepatitis B: Reflections on the current approach to antiviral therapy

Journal of Hepatology

Volumn 48, Issue SUPPL. 1, 2008, Pages

  Zoulim, Fabien ^a,b,c   Perrillo, Robert ^d  

^a INSERM   (France)

^b UNIVERSITÉ LYON 1   (France)

^c HÔTEL DIEU   (France)

^d BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antiviral therapy combination therapy; Hepatitis B; Monotherapy; Rescue therapy

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ALPHA2A INTERFERON; ANTIVIRUS AGENT; CLEVUDINE; EMTRICITABINE; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

ADD ON THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; CHRONIC HEPATITIS; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE ACTIVITY; DRUG INHIBITION; DRUG MECHANISM; DRUG SUBSTITUTION; FOLLOW UP; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER FIBROSIS; MONOTHERAPY; MORTALITY; MULTIDRUG RESISTANCE; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SEROCONVERSION; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS REPLICATION;

ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DNA, VIRAL; HEPATITIS B; HUMANS; INTERFERONS; TREATMENT OUTCOME;

EID: 40849105240     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2008.01.011     Document Type: Review

References (139)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 11 (2004) 97-107
2. WHO. Hepatitis B vaccines. Wkly Epidemiol Rec 2004;79:255-263.
3. Fattovich G. Natural history of hepatitis B. J Hepatol 39 (2003) S50-S58
4. Perrillo R.P. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 120 (2001) 1009-1022
5. Rehermann B. Immune responses in hepatitis B virus infection. Semin Liver Dis 23 (2003) 21-38
6. Perrillo R.P., Lai C.L., Liaw Y.F., Dienstag J.L., Schiff E.R., Schalm S.W., et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 36 (2002) 186-194
7. Lok A.S., and McMahon B.J. Chronic hepatitis B. Hepatology 45 (2007) 507-539
8. de Franchis R, Hadengue A, Lau G, Lavanchy D, Lok A, McIntyre N, et al. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol 2003;39:S3-S25.
9. Liaw YF, Leung N, Guan R, Lau GK, Merican I, McCaughan G, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 2005;25:472-489.
10. Chu C.J., Hussain M., and Lok A.S. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology 36 (2002) 1408-1415
11. Manesis E.K., Papatheodoridis G.V., Sevastianos V., Cholongitas E., Papaioannou C., and Hadziyannis S.J. Significance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction assay in patients with hepatitis B e antigen-negative chronic hepatitis B virus infection. Am J Gastroenterol 98 (2003) 2261-2267
12. Papatheodoridis G., Manesis E., Manolakopoulos S., Goulis J., Chrysanthos N., Bilalis A., et al. HBeAg-negative chronic hepatitis B (CHBe-) in chronic HBV patients with serum HBV-DNA levels below 2000 IU/mL. J Hepatol 46 (2007) S183
13. Bonino F., and Brunetto M.R. Chronic hepatitis B e antigen (HBeAg) negative, anti-HBe positive hepatitis B: an overview. J Hepatol 39 (2003) S160-S163
14. Piton A., Poynard T., Imbert-Bismut F., Khalil L., Delattre J., Pelissier E., et al. Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group. Hepatology 27 (1998) 1213-1219
15. Kim H.C., Nam C.M., Jee S.H., Han K.H., Oh D.K., and Suh I. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ 328 (2004) 983
16. Yang L., Xu K., Zhao Y., Wu Z., Chen T., Qin Z., et al. Clinical significance of liver biopsy in chronic hepatitis B patients with persistently normal transaminase. Chin J Dig Dis 3 (2002) 150-153
17. Mohamadnejad M., Montazeri G., Fazlollahi A., Zamani F., Nasiri J., Nobakht H., et al. Noninvasive markers of liver fibrosis and inflammation in chronic hepatitis B-virus related liver disease. Am J Gastroenterol 101 (2006) 2537-2545
18. Yuen M.F., Yuan H.J., Wong D.K., Yuen J.C., Wong W.M., Chan A.O., et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut 54 (2005) 1610-1614
19. Lai C.L., and Yuen M.F. The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points. Ann Intern Med 147 (2007) 58-61
20. Keeffe E.B., Dieterich D.T., Han S.H., Jacobson I.M., Martin P., Schiff E.R., et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 4 (2006) 936-962
21. Perrillo R.P., Gish R.G., Peters M., Keeffe E.B., Alberti A., Buti M., et al. Chronic hepatitis B: a critical appraisal of current approaches to therapy. Clin Gastroenterol Hepatol 4 (2006) 233-248
22. Yang H.I., Lu S.N., Liaw Y.F., You S.L., Sun C.A., Wang L.Y., et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 347 (2002) 168-174
23. Iloeje U.H., Yang H.I., Su J., Jen C.L., You S.L., and Chen C.J. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130 (2006) 678-686
24. Yu M.W., Yeh S.H., Chen P.J., Liaw Y.F., Lin C.L., Liu C.J., et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 97 (2005) 265-272
25. Chen G., Shen F.M., Iloeje U.H., and Evans A. Viral load as a predictor of liver disease in chronic hepatitis B infection. Hepatology 40 (2004) 594A
26. Iloeje U., Yang H., Su J., Jen C., Kuo E., You S., et al. Viral load is a strong predictor of hepatocellular carcinoma risk in people chronically infected with hepatitis B virus and normal serum alanine aminotransferase level. J Hepatol 42 (2005) 179
27. Evans A., Fabre R., Chen G., Pasternak L., Iloeje U., and London W. Hepatitis B viral load is associated with the development of hepatocellular carcinoma. Hepatology 40 (2004) 602A
28. Chen G., Lin W., Shen F., Iloeje U., London W., and Evans A. Viral load as a predictor of mortality from hepatocellular carcinoma and chronic liver disease in chronic hepatitis B infection. J Hepatol 42 (2005) 173
29. Chen C.J., Yang H.I., Su J., Jen C.L., You S.L., Lu S.N., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295 (2006) 65-73
30. Perrillo R. Hepatitis B virus replication × time equals trouble. Gastroenterology 130 (2006) 989-991
31. Liaw Y.F., Sung J.J., Chow W.C., Farrell G., Lee C.Z., Yuen H., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 (2004) 1521-1531
32. Sherman M. Predicting survival in hepatitis B. Gut 54 (2005) 1521-1523
33. Hui C.K., Leung N., Yuen S.T., Zhang H.Y., Leung K.W., Lu L., et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. Hepatology 46 (2007) 395-401
34. Lin C.L., Liao L.Y., Liu C.J., Yu M.W., Chen P.J., Lai M.Y., et al. Hepatitis B viral factors in HBeAg-negative carriers with persistently normal serum alanine aminotransferase levels. Hepatology 45 (2007) 1193-1198
35. Prati D., Taioli E., Zanella A., Della Torre E., Butelli S., Del Vecchio E., et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 137 (2002) 1-10
36. Rang A., Bruns M., Heise T., and Will H. Antiviral activity of interferon-alpha against hepatitis B virus can be studied in non-hepatic cells and is independent of MxA. J Biol Chem 277 (2002) 7645-7647
37. Peters M., Walling D.M., Waggoner J., Avigan M.I., Sjogren M., and Hoofnagle J.H. Immune effects of alpha-interferon in chronic liver disease. J Hepatol 3 (1986) S283-S289
38. Perrillo R.P., Schiff E.R., Davis G.L., Bodenheimer Jr. H.C., Lindsay K., Payne J., et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med 323 (1990) 295-301
39. Cooksley W.G., Piratvisuth T., Lee S.D., Mahachai V., Chao Y.C., Tanwandee T., et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 10 (2003) 298-305
40. Janssen H.L., van Zonneveld M., Senturk H., Zeuzem S., Akarca U.S., Cakaloglu Y., et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365 (2005) 123-129
41. Lau G.K., Piratvisuth T., Luo K.X., Marcellin P., Thongsawat S., Cooksley G., et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352 (2005) 2682-2695
42. Marcellin P., Lau G.K., Bonino F., Farci P., Hadziyannis S., Jin R., et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 351 (2004) 1206-1217
43. Nair S., and Perrillo R.P. Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: is sustained clearance of HBV DNA dependent on levels of pretreatment viremia?. Hepatology 34 (2001) 1021-1026
44. Flink H.J., Sprengers D., Hansen B.E., van Zonneveld M., de Man R.A., Schalm S.W., et al. Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during peg-interferon {alpha}-2b therapy. Gut 54 (2005) 1604-1609
45. van Zonneveld M., Honkoop P., Hansen B.E., Niesters H.G., Murad S.D., de Man R.A., et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 39 (2004) 804-810
46. Lau D.T., Everhart J., Kleiner D.E., Park Y., Vergalla J., Schmid P., et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 113 (1997) 1660-1667
47. Flink H.J., van Zonneveld M., Hansen B.E., de Man R.A., Schalm S.W., and Janssen H.L. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol 101 (2006) 297-303
48. ®), peginterferon α-2a plus lamivudine and lamivudine in HBeAg-positive chronic hepatitis B. J Hepatol 42 (2005) 189
49. ®) in HBeAg-positive chronic hepatitis B: Results from a large, randomized study. J Hepatol 42 (2005) 31
50. Bonino F., Marcellin P., Lau G.K., Hadziyannis S., Jin R., Piratvisuth T., et al. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 56 (2007) 699-705
51. Marcellin P., Bonino F., Lau G., Farci P., Yurdaydin C., Piratvisuth T., et al. Virological and biochemical response in patients with HBeAg-negative CHB treated with peginterferon α-2a (40 kDa) ± lamivudine: 3-year follow-up results. J Hepatol 46 (2007) S25
52. Chan H.L., Hui A.Y., Wong V.W., Chim A.M., Wong M.L., and Sung J.J. Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B. Hepatology 41 (2005) 1357-1364
53. Chan H.L., Leung N.W., Hui A.Y., Wong V.W., Liew C.T., Chim A.M., et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med 142 (2005) 240-250
54. Lutgethetmann M., Wursthorn K., Buggisch P., Zollner B., Zankel M., Fischer C., et al. 48 weeks of adefovir mono therapy following 48 weeks of combination therapy with peginterferon alpha-2b and adefovir leads to additional biochemical and virological improvement. J Hepatol 44 (2007) S189
55. Wursthorn K., Lutgehetmann M., Dandri M., Volz T., Buggisch P., Zollner B., et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 44 (2006) 675-684
56. Sarin S.K., Sood A., Kumar M., Arora A., Amrapurkar D., Sharma B.C., et al. Effect of lowering HBV DNA levels by initial antiviral therapy before adding immunomodulator on treatment of chronic hepatitis B. Am J Gastroenterol 102 (2007) 96-104
57. Manesis E.K., and Hadziyannis S.J. Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 121 (2001) 101-109
58. Lampertico P., Del Ninno E., Vigano M., Romeo R., Donato M.F., Sablon E., et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology 37 (2003) 756-763
59. Manesis E., Hadziyannis S., Agelopoulou O., and Hadziyannis S. HBsAg levels under interferon and lamivudine therapy in HBeAg-negative chronic hepatitis B (CHBe-) patients. J Hepatol 42 (2005) 185
60. Gish R.G., Lau D.T., Schmid P., and Perrillo R. A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B. Am J Gastroenterol 102 (2007) 2718-2723
61. Buster E.H., and Janssen H.L. Antiviral treatment for chronic hepatitis B virus infection - immune modulation or viral suppression?. Neth J Med 64 (2006) 175-185
62. Perrillo R.P. Therapy of hepatitis B - viral suppression or eradication?. Hepatology 43 (2006) S182-S193
63. Zoulim F. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antiviral Res 64 (2004) 1-15
64. Seigneres B., Pichoud C., Martin P., Furman P., Trepo C., and Zoulim F. Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses. Hepatology 36 (2002) 710-722
65. Zoulim F., Dannaoui E., Borel C., Hantz O., Lin T.S., Liu S.H., et al. 2′,3′-Dideoxy-beta-l-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo. Antimicrob Agents Chemother 40 (1996) 448-453
66. Delaney W., Ray A.S., Yang H., Qi X., Xiong S., Zhu Y., et al. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother 50 (2006) 2471-2477
67. Seigneres B., Aguesse-Germon S., Pichoud C., Vuillermoz I., Jamard C., Trepo C., et al. Duck hepatitis B virus polymerase gene mutants associated with resistance to lamivudine have a decreased replication capacity in vitro and in vivo. J Hepatol 34 (2001) 114-122
68. Seifer M., Hamatake R.K., Colonno R.J., and Standring D.N. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob Agents Chemother 42 (1998) 3200-3208
69. Standring D.N., Bridges E.G., Placidi L., Faraj A., Loi A.G., Pierra C., et al. Antiviral beta-l-nucleosides specific for hepatitis B virus infection. Antivir Chem Chemother 12 (2001) 119-129
70. Delaney W., Yang H., Miller M.D., Gibbs C.S., and Xiong S. Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro. Antimicrob Agents Chemother 48 (2004) 3702-3710
71. Seigneres B., Martin P., Werle B., Schorr O., Jamard C., Rimsky L., et al. Effects of pyrimidine and purine analog combinations in the duck hepatitis B virus infection model. Antimicrob Agents Chemother 47 (2003) 1842-1852
72. Lai C.L., Leung N., Teo E.K., Tong M., Wong F., Hann H.W., et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 129 (2005) 528-536
73. Sung J.J.Y., Lai J.-Y., Zeuzem S., Chow W.C., Heathcote E.J., Perrillo R.P., et al. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol 48 (2008) 728-735
74. Delmas J., Schorr O., Jamard C., Gibbs C., Trepo C., Hantz O., et al. Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro. Antimicrob Agents Chemother 46 (2002) 425-433
75. Kock J., Baumert T.F., Delaney W., Blum H.E., and von Weizsacker F. Inhibitory effect of adefovir and lamivudine on the initiation of hepatitis B virus infection in primary tupaia hepatocytes. Hepatology 38 (2003) 1410-1418
76. Moraleda G., Saputelli J., Aldrich C.E., Averett D., Condreay L., and Mason W.S. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J Virol 71 (1997) 9392-9399
77. Zhu Y., Yamamoto T., Cullen J., Saputelli J., Aldrich C.E., Miller D.S., et al. Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J Virol 75 (2001) 311-322
78. Summers J., and Mason W.S. Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy. Proc Natl Acad Sci USA 101 (2004) 638-640
79. Yokosuka O., Omata M., Imazeki F., Okuda K., and Summers J. Changes of hepatitis B virus DNA in liver and serum caused by recombinant leukocyte interferon treatment: analysis of intrahepatic replicative hepatitis B virus DNA. Hepatology 5 (1985) 728-734
80. Sung J.J., Wong M.L., Bowden S., Liew C.T., Hui A.Y., Wong V.W., et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 128 (2005) 1890-1897
81. Werle-Lapostolle B., Bowden S., Locarnini S., Wursthorn K., Petersen J., Lau G., et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 126 (2004) 1750-1758
82. Maynard M., Parvaz P., Durantel S., Chevallier M., Chevallier P., Lot M., et al. Sustained HBs seroconversion during lamivudine and adefovir dipivoxil combination therapy for lamivudine failure. J Hepatol 42 (2005) 279-281
83. Lai C.L., Dienstag J., Schiff E., Leung N.W., Atkins M., Hunt C., et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 36 (2003) 687-696
84. Lok A.S., Lai C.L., Leung N., Yao G.B., Cui Z.Y., Schiff E.R., et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125 (2003) 1714-1722
85. van Zonneveld M., van Nunen A.B., Niesters H.G., de Man R.A., Schalm S.W., and Janssen H.L. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat 10 (2003) 294-297
86. Tillmann H.L., Hadem J., Leifeld L., Zachou K., Canbay A., Eisenbach C., et al. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat 13 (2006) 256-263
87. Lau G.K., He M.L., Fong D.Y., Bartholomeusz A., Au W.Y., Lie A.K., et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology 36 (2002) 702-709
88. Lau G.K., Yiu H.H., Fong D.Y., Cheng H.C., Au W.Y., Lai L.S., et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 125 (2003) 1742-1749
89. Zoulim F., Poynard T., Degos F., Slama A., El Hasnaoui A., Blin P., et al. A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine. J Viral Hepat 13 (2006) 278-288
90. Perrillo R., Hann H.W., Mutimer D., Willems B., Leung N., Lee W.M., et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 126 (2004) 81-90
91. Peters M.G., Hann Hw H., Martin P., Heathcote E.J., Buggisch P., Rubin R., et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 126 (2004) 91-101
92. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., Chang T.T., Kitis G., Rizzetto M., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 348 (2003) 800-807
93. Marcellin P., Chang T.T., Lim S.G., Tong M.J., Sievert W., Shiffman M.L., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 348 (2003) 808-816
94. Durantel S, Werle B, Durantel D, Pichoud C, Currie G, Xiong S, et al. Different profiles of response to adefovir dipivoxil and factors that may influence response in patients with chronic hepatitis B. Antiviral Therapy, in press.
95. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., Chang T.T., Kitis G., Rizzetto M., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 131 (2006) 1743-1751
96. Lampertico P., Vigano M., Manenti E., Iavarone M., Lunghi G., and Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 42 (2005) 1414-1419
97. Lampertico P., Marzano A., Levrero M., Santantonio T., Di Marco V., Brunetto M., et al. Adefovir and lamivudine combination therapy is superior to adefovir monotherapy for lamivudine-resistant patients with HBeAg-negative chronic hepatitis B. Hepatology 44 (2006) 693A
98. Chang T.T., Gish R.G., de Man R., Gadano A., Sollano J., Chao Y.C., et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354 (2006) 1001-1010
99. Lai C.L., Shouval D., Lok A.S., Chang T.T., Cheinquer H., Goodman Z., et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 354 (2006) 1011-1020
100. Colonno R.J., Rose R., Baldick C.J., Levine S., Pokornowski K., Yu C.F., et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 44 (2006) 1656-1665
101. Sherman M., Yurdaydin C., Sollano J., Silva M., Liaw Y.F., Cianciara J., et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 130 (2006) 2039-2049
102. Tenney D.J., Rose R.E., Baldick C.J., Levine S.M., Pokornowski K.A., Walsh A.W., et al. Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 51 (2007) 902-911
103. Tenney D.J., Levine S.M., Rose R.E., Walsh A.W., Weinheimer S.P., Discotto L., et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 48 (2004) 3498-3507
104. Villet S., Ollivet A., Pichoud C., Barraud L., Villeneuve J.P., Trepo C., et al. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol 46 (2007) 531-538
105. McMahon M.A., Jilek B.L., Brennan T.P., Shen L., Zhou Y., Wind-Rotolo M., et al. The HBV drug entecavir - effects on HIV-1 replication and resistance. N Engl J Med 356 (2007) 2614-2621
106. Chan H.L., Heathcote E.J., Marcellin P., Lai C.L., Cho M., Moon Y.M., et al. Treatment of hepatitis B e antigen-positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med 147 (2007) 745-754
107. Lai C.L., Gane E., Liaw Y.F., Hsu C.W., Thongsawat S., Wang Y., et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 357 (2007) 2576-2588
108. van Bommel F., Wunsche T., Mauss S., Reinke P., Bergk A., Schurmann D., et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 40 (2004) 1421-1425
109. van Bommel F., Zollner B., Sarrazin C., Spengler U., Huppe D., Moller B., et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 44 (2006) 318-325
110. Benhamou Y., Tubiana R., and Thibault V. Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. N Engl J Med 348 (2003) 177-178
111. Dore G.J., Cooper D.A., Pozniak A.L., DeJesus E., Zhong L., Miller M.D., et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 189 (2004) 1185-1192
112. Lacombe K., Gozlan J., Boelle P.Y., Serfaty L., Zoulim F., Valleron A.J., et al. Long-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate. Aids 19 (2005) 907-915
113. Peters M.G., Andersen J., Lynch P., Liu T., Alston-Smith B., Brosgart C.L., et al. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology 44 (2006) 1110-1116
114. Marcellin P., Buti M., Krastev Z., Germanidis G., Kaita K.D., Kotzev I., et al. A randomized double blind comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg-negative chronic hepatitis B (CHB). Hepatology 46 (2007) 290A
115. Heathcote E.J., Gane E., DeMan R., Lee S., Flisiak R., Manns M.P., et al. A randomized double blind comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg-positive chronic hepatitis B (CHB). Hepatology 46 (2007) 861A
116. Locarnini S., Hatzakis A., Heathcote J., Keeffe E.B., Liang T.J., Mutimer D., et al. Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther 9 (2004) 679-693
117. Di Bisceglie A.M., Lai C.L., Gane E., Chen Y.-C., Thongsawat S., Wang Y., et al. Telbivudine globe trial: maximal early HBV suppression is predictive of optimal two-year efficacy in nucleoside-treated hepatitis B patients. Hepatology 44 (2006) 230A
118. Keeffe E.B., Zeuzem S., Koff R.S., Dieterich D.T., Esteban-Mur R., Gane E.J., et al. Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 5 (2007) 890-897
119. Lok A.S., Zoulim F., Locarnini S., Bartholomeusz A., Ghany M.G., Pawlotsky J.M., et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 46 (2007) 254-265
120. Nafa S., Ahmed S., Tavan D., Pichoud C., Berby F., Stuyver L., et al. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 32 (2000) 1078-1088
121. Allen M.I., Deslauriers M., Andrews C.W., Tipples G.A., Walters K.A., Tyrrell D.L., et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine clinical investigation group. Hepatology 27 (1998) 1670-1677
122. Yang H., Qi X., Sabogal A., Miller M., Xiong S., and Delaney W. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther 10 (2005) 625-633
123. Angus P., Vaughan R., Xiong S., Yang H., Delaney W., Gibbs C., et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 125 (2003) 292-297
124. Villeneuve J.P., Durantel D., Durantel S., Westland C., Xiong S., Brosgart C.L., et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 39 (2003) 1085-1089
125. Villet S., Pichoud C., Villeneuve J.P., Trepo C., and Zoulim F. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology 131 (2006) 1253-1261
126. Qi X., Xiong S., Yang H., Miller M., and Delaney W. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther 12 (2007) 355-362
127. Schildgen O., Sirma H., Funk A., Olotu C., Wend U.C., Hartmann H., et al. Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med 354 (2006) 1807-1812
128. Curtis M., Zhu Y., and Borroto-Esoda K. Hepatitis B virus containing the I233V mutation in the polymerase reverse-transcriptase domain remains sensitive to inhibition by adefovir. J Infect Dis 196 (2007) 1483-1486
129. Sheldon J., Camino N., Rodes B., Bartholomeusz A., Kuiper M., Tacke F., et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 10 (2005) 727-734
130. Yim H.J., Hussain M., Liu Y., Wong S.N., Fung S.K., and Lok A.S. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 44 (2006) 703-712
131. Brunelle M.N., Jacquard A.C., Pichoud C., Durantel D., Carrouee-Durantel S., Villeneuve J.P., et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 41 (2005) 1391-1398
132. Lampertico P., Vigano M., Manenti E., Iavarone M., Sablon E., and Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 133 (2007) 1445-1451
133. Zoulim F. Antiviral therapy of chronic hepatitis B. Antiviral Res 71 (2006) 206-215
134. Yuen M.F., Fong D.Y., Wong D.K., Yuen J.C., Fung J., and Lai C.L. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Hepatology 46 (2007) 1695-1703
135. Stuyver L., Van Geyt C., De Gendt S., Van Reybroeck G., Zoulim F., Leroux-Roels G., et al. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy. J Clin Microbiol 38 (2000) 702-707
136. Clavel F., and Hance A.J. HIV drug resistance. N Engl J Med 350 (2004) 1023-1035
137. Hui C.-K., Zhang H.-Y., Bowden S., Locarnini S., Luk J.M., Leung K.-W., et al. 96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B. J Hepatol 48 (2008) 714-720
138. Litwin S., Toll E., Jilbert A.R., and Mason W.S. The competing roles of virus replication and hepatocyte death rates in the emergence of drug-resistant mutants: theoretical considerations. J Clin Virol 34 (2005) S96-S107
139. Brunelle M.N., Lucifora J., Neyts J., Villet S., Holy A., Trepo C., et al. In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants. Antimicrob Agents Chemother 51 (2007) 2240-2243